VolitionRX (NYSEAMERICAN:VNRX) Posts Quarterly Earnings Results, Misses Expectations By $0.27 EPS

VolitionRX (NYSEAMERICAN:VNRX) released its quarterly earnings data on Thursday. The medical research company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.27), FiscalAI reports. The company had revenue of $0.99 million for the quarter, compared to analysts’ expectations of $1.52 million.

VolitionRX Price Performance

VNRX traded down $0.16 during midday trading on Thursday, reaching $2.20. 103,794 shares of the company’s stock were exchanged, compared to its average volume of 262,034. VolitionRX has a 1-year low of $2.01 and a 1-year high of $18.80. The stock has a market capitalization of $17.80 million, a PE ratio of -0.50 and a beta of 1.03. The business’s 50-day moving average price is $3.35 and its 200 day moving average price is $4.98.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Virtu Financial LLC purchased a new stake in VolitionRX in the 3rd quarter valued at approximately $28,000. Northwestern Mutual Wealth Management Co. purchased a new position in VolitionRX during the second quarter worth $52,000. Geode Capital Management LLC raised its holdings in shares of VolitionRX by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after acquiring an additional 85,816 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of VolitionRX in the fourth quarter worth $28,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of VolitionRX in the fourth quarter valued at $34,000. 8.09% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. D. Boral Capital reiterated a “hold” rating on shares of VolitionRX in a research report on Monday, April 20th. Citigroup downgraded VolitionRX to a “hold” rating in a research note on Monday, April 20th. Finally, HC Wainwright reduced their price objective on VolitionRX from $30.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, VolitionRX presently has an average rating of “Moderate Buy” and an average price target of $46.67.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.